Abstract
A retrospective study was performed to determine whether the long-term (5 years or more) administration of tamoxifen is detrimental to bone mineral density (BMD). 19 patients taking adjuvant tamoxifen for breast cancer were paired with 19 controls comparable in age, time since menopause and performance status. BMD was measured at the femoral neck, lumbar spine and total body by dual energy X-ray absorptiometry (DEXA). There was no detrimental effect on BMD at any site. There was a trend towards an increase in BMD at the femoral neck. There were minor decreases in the serum calcium, phosphate and alkaline phosphatase.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
